Trials / Completed
CompletedNCT00687505
Safety Study of FP-1039 To Treat Cancer
A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Five Prime Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FP-1039 | Intravenous weekly administration |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-05-01
- Completion
- 2011-06-01
- First posted
- 2008-05-30
- Last updated
- 2021-12-13
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00687505. Inclusion in this directory is not an endorsement.